NCT04446962View on ClinicalTrials.gov

LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

February 2, 2035

Study Completion Date

August 30, 2035

Conditions
Lymphoma, Large B-Cell, DiffuseCentral Nervous System Neoplasms, Primary
Interventions
DRUG

Lenalidomide

Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.

DRUG

Ibrutinib

Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.

Trial Locations (28)

30029

CHU Nîmes - Carémeau, Nîmes

35000

CHU Rennes, Rennes

64100

CH côte Basque, Bayonne

67098

CHU Strasbourg-Hôpital Hautepierre, Strasbourg

69000

CHRU Lille, Lille

75005

Institut Curie, Paris

75006

Hôpital Cochin, Paris

75013

CHU Pitié-Salpêtrière, Paris

76000

Centre Henri Becquerel, Rouen

Unknown

CHU Amiens, Amiens

CHU Angers, Angers

CHU Besançon, Besançon

Institut Bergonié, Bordeaux

CHU Caen, Caen

CHU Clermont-Ferrand, Clermont-Ferrand

CH Colmar, Colmar

CHU Créteil, Créteil

CHU Dijon, Dijon

CHU Grenoble, Grenoble

CHU Limoges, Limoges

CHU Lyon, Lyon

CHU La Timone Marseille, Marseille

CHU Nancy, Nancy

CHU Nantes, Nantes

Centre Lacassagne, Nice

CHU Poitiers, Poitiers

IUCT -Oncopole, Toulouse

CHU Tours, Tours

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

lead

Institut Curie

OTHER